

## **Murine Anti-Factor VIII**

## Clone GMA-8005


Factor VIII (FVIII) is a heterodimer consisting of a heavy chain (ranging in mass from 90 to 200 kDa) bound via metal ions to a light chain (80 kDa). In plasma, FVIII circulates in an inactive form bound to von Willebrand factor. Following activation by factor Xa or thrombin, factor VIIIa can function as cofactor for the enzyme factor IXa in the activation of factor X in the presence of phospholipid and Ca<sup>2+</sup>. Absent or defective FVIII is the cause of the X-linked recessive bleeding disorder hemophilia A. GMA-8005 recognizes the A1 domains of FVIII, and is suitable for ELISA applications and bio-layer interferometry pairing experiments.

_			
Des	crı	ptic	n

Antibody Source:	mouse monoclonal, IgG <sub>2b</sub>
Antigen Species Bound:	human
Specificity:	FVIII A1 domain
Immunogen:	B-domain deleted recombinant human FVIII

Immunogen:	B-domain deleted recombinant human FVIII		
Formulation and Storage			
Purity:	Purified by protein G affinity chromatography from serum-free cell culture supernatant.		
Product Formulation:	Lyophilized from a $\geq 1$ mg/ml solution in 20 mM NaH <sub>2</sub> PO <sub>4</sub> 0.15 M NaCl, 1.0% (w/v) mannitol, pH 7.4. Concentration determined by absorbance measurement at 280 nm and using an extinction coefficient of 1.4 ( $\epsilon_{0.1\%}$ ).		
Reconstitution:	Reconstitute with deionized water.		
Storage:	Store lyophilized or reconstituted and aliquoted material at -20°C for prolonged periods. Avoid freeze-thaw cycles. Alternatively, add 0.02% (w/v) sodium azide to reconstituted solution and store at 4°C.		
Country of Origin:	USA		
Size Options:	0.1 mg or 0.5 mg		

Applications		
Working Concentration:	Approximately 1-5 μg/ml. Researcher should titer antibody in specific assay.	
ELISA:	Binds immobilized human FVIII.	
Immunoblotting:	Not recommended.	
Inhibition:	Does not inhibit in aPTT clotting	
minibition.	assay.	



## References

[1] S. Krishnamoorthy, T. Liu, D. Drager, S. Patarroyo-White, E.S. Chhabra, R. Peters, N. Josephson, D. Lillicrap, R.S. Blumberg, G.F. Pierce, H. Jiang. Recombinant factor VIII Fc (rFVIIIFc) fusion protein reduces immunogenicity and induces tolerance in hemophilia A mice. (2016). *Cell Immunol.* 301:30-39.

For in vitro research only. Not for use as a diagnostic or therapeutic. All sales governed by Warranty Policy located at: https://greenmoab.com/about-gma/warranty-policy/